Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
If you have questions about our programs, contact us now
The Phase 2 trial published in 2023 (Jastreboff et al., New England Journal of Medicine) demonstrated impressive short-term weight loss, but long-term data particularly beyond 48 weeks remain limited
It has since been approved for weight loss which has caused demand to increase dramatically in the past year
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways
US$ 21.24
US$ 26.27
US$ 22.80
US$ 24.30
US$ 21.03
